Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair  by Chen, Jun et al.
see commentary on page 847
Kidney-derived mesenchymal stem cells contribute to
vasculogenesis, angiogenesis and endothelial repair
Jun Chen1,3, Hyeong-Cheon Park1,2,3, Francesco Addabbo1, Jie Ni1, Edward Pelger1, Houwei Li1,
Matthew Plotkin1 and Michael S. Goligorsky1
1Departments of Medicine and Pharmacology, New York Medical College, Valhalla, New York, USA and 2Department of Internal
Medicine, College of Medicine, Yonsei University, Seoul, Korea
We isolated a clonal cell line (4E) from kidneys of mice
expressing green fluorescent protein controlled by the
endothelial-specific Tie2 promoter. When grown in a
three-dimensional matrigel matrix they formed a fluorescent
capillary network. In vivo angiogenesis assays using growth
factor-depleted matrigel implanted plugs promoted a
moderate angiogenesis of host endothelial cells. Using
vascular endothelial growth factor (VEGF)-A and fibroblast
growth factor-2 in the plugs containing 4E-cells resulted in a
robust vasculogenesis. Transplantation of 4E cells into mice
with acute renal ischemia showed selective engraftment in
the ischemic kidney which promoted tubular regeneration by
increasing epithelial proliferation and inhibiting apoptosis.
This resulted in an accelerated functional recovery 3 days
after ischemia. These mice showed a 5-fold increase in tissue
VEGF expression compared to controls, but no difference in
plasma VEGF level corresponding with better preservation of
peritubular capillaries, perhaps due to a local paracrine effect
following systemic 4E infusion. One month after ischemia,
9% of engrafted 4E cells expressed green fluorescent protein
in the peritubular region while half of them expressed
a-smooth muscle actin. Our study shows that kidney
mesenchymal stem cells are capable of differentiation toward
endothelial and smooth muscle cell lineages in vitro and
in vivo, support new blood vessel formation in favorable
conditions and promote functional recovery of an ischemic
kidney.
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Sinusoidal endothelium in bone marrow and extraosseous
capillaries represent a large disseminated niche for mesen-
chymal stem cells (MSC), which are present, according to
the recent study, in practically all postnatal organs and tissues
tested.1 This disseminated pool of MSC localized to the
basement membrane of blood vessels in close contact with
the vascular endothelium may be involved in the local
regulation of vascular and/or tissue regeneration. Whereas
osteoblastic bone marrow niche provides microenvironment
supportive of stem cell quiescence, the vascular niche
facilitates their proliferation, differentiation, and rapid
mobilization.2 These perivascular stem cells are, in part,
represented by pericyte-like MSCs also termed mural stem
cells.1 MSCs have the potential to differentiate along multiple
lineages in vitro, including the best characterized osteogenic,
chondrogenic, and adipogenic differentiation,3,4 although,
according to the recent data, these cells can differentiate
toward endothelial cell lineage.5–8 The latter claim rests on
the use of bone marrow-derived MSC in a canine model of
chronic cardiac ischemia in which MSCs were found to be
colocalized with endothelial and smooth muscle cells, but not
with cardiomyocytes, 1 month after transplantation. This was
associated with a trend toward reduced fibrosis and increased
vascular density. Weekly injections of MSC in collagen4A3-
deficient mice, a model of Alport syndrome, resulted in the
reduction of renal fibrosis and prevention of the loss of
peritubular capillaries in conjunction with the localization of
transplanted cells in peritubular capillaries.9 Conflicting
results demonstrating no morphologic improvement after
MSC transplantation, as opposed to therapeutic efficacy of
transplanting bone marrow-derived cells, in the model have
been reported by Prodromidi et al.10 An account on the
differentiation of isolated bone marrow-derived MSC
cultured in a medium containing vascular endothelial growth
factor into endothelial cells in vitro has been published by
Oswald et al.11 and Togel et al.12 The apparent paucity of data
on the differentiation potential of MSC toward endothelial
lineage, especially in vivo, and the absence of published data
on organ-derived MSC prompted us to investigate these
issues. Our main goal was to elucidate the possible differen-
tiation repertoire of local MSC and their contribution to
tissue protection. Specifically, this study was designed to
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address this possibility both in vitro and in vivo. Using a
clonal cell line of MSC (4E) isolated from the kidney of adult
Tie-2 green fluorescent protein (GFP) transgenic FVB/NJ
mice,8 we examined their in vitro and in vivo angiogenic and
vasculogenic properties and further tested their differentia-
tion potential in mice with acute ischemic renal injury.
RESULTS
In vitro angiogenesis
To examine the possibility that MSC can differentiate toward
endothelial lineage, we tested their in vitro angiogenic
potential using 4E cells. These cells were cloned from a
single colony of the original MSC isolated from the kidney of
Tie-2/GFP mice and thoroughly characterized,8 thus negating
any contamination with endothelial cells. As illustrated in
Figure 1a, when cultured on three-dimensional matrigel in
EGM-2 medium, 4E cells initially formed ‘sphere’-like
structures, which gradually spread out forming a dense
capillary network. Some cells in these capillaries showed
positive GFP signals. Fluorescence-activated cell sorter
analysis of isolated capillary-forming cells cultured for 30
days indicated that about 14.8% were double positive for
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Figure 1 | In vitro differentiation of 4E cells into endothelial- and smooth muscle-like cells. (a) The 4E initially formed ‘sphere’-like
structure that gradually spread out forming numerous capillaries. Acquisition of GFPþ signal by these cells and their morphology are
illustrated. (b) FASC analysis of 4E cells maintained in MSC culture medium showed the absence of GFP/CD31 double-positive cells, further
confirming that these cells initially did not contain endothelial cells (left panel). However, when 4E cells were cultured for 30 days in
matrigel/EGM-2 medium, 14.8% cells were GFP/CD31 double-positive (right panel), whereas only 3.65% became double positive in
fibronectin/EGM-2 medium (middle panel). (c) The 4E cells differentiated into smooth muscle-like cells expressing aSMA, but not Tie2-GFP,
when cultured in MSC medium (upper panel). In contrast, 4E cells differentiated into endothelial-like cells expressing Tie2-GFP, but not
aSMA, when cultured on matrigel in EGM-2 medium (c).
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GFP/CD31 (under matrigel/EGM-2 medium culture condi-
tions) as opposed to the original 4E MSC population
negative for these markers (Figure 1b). When cultured in
EGM-2 or MSC culture medium, 4E cells displayed scattered
appearance of endothelial (Tie2-GFP) and a-smooth muscle
actin (aSMA) cell markers (Figure 1c), revealing the alter-
native acquisition of either the endothelial or the smooth
muscle cell phenotypical markers depending on the ambient
conditions, namely EGM-2 or MSC medium, respectively.
In vivo neovascularization of angioreactors
We next studied the angiogenic and/or vasculogenic potential
of kidney MSC (4E cells) in vivo using matrigel-filled
implantable angioreactors (directed in vivo angiogenesis
assay). Control angioreactors, which contained only growth
factor-depleted matrigel, revealed no capillary ingrowth.
Second control group, angioreactors containing growth
factors only, showed a robust ingrowth of host capillaries.
The 4E-containing angioreactors, within 15 days of implan-
tation, showed an intense angiogenesis originating from the
host endothelial cells and a modest vasculogenesis (Figure 2).
These neovessels were apparently patent and functional, as
they were stained positive for Lycopersicon Esculentum lectin
(LEL)-FITC, administered before harvesting the subcuta-
neously implanted angioreactors. Considering the fact that
majority of neovessels originated from the host endothelium,
these results are consistent with the paracrine signaling
hypothesis.8 The 4E cells promoted the in vivo angiogenesis,
presumably, through the secretion of pro-angiogenic factors
and chemoattraction of the host endothelial cells.
When growth factors, vascular endothelial growth factor-
A/fibroblast growth factor-2 (VEGF-A/FGF-2), were added to
the 4E-containing matrigel angioreactors, a robust neovas-
cularization occurred, in which functional (LEL-FITC-
positive) vascular network was formed. We documented that
the CM-DiI-labeled 4E cells were recruited into the
neovasculature, when the exogenous growth factors were
presented. The number of the capillary-associated 4E cells
was significantly higher in the growth factor-containing
group (57.46±7.15%) compared with the 4E growth factor-
free angioreactors (8.54±3.01%) (Figure 2, inset). The high-
magnification images of the neovasculature in Figure 2 (right
panel) illustrate that, in the growth factor-containing
matrigel, the majority of CM-DiI-labeled 4E cells recruited
to the vessels were also GFP-positive, suggesting that these
capillaries were formed through vasculogenesis, specifically
via the differentiation of 4E cells to endothelial cells. This
green fluorescent signal could be attributed to either Tie2-
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Figure 2 | In vivo contribution of 4E cells to neovascularization of angioreactors. Fifteen days after subcutaneous implantation of
angioreactors, 4E cells promoted the invasion of endothelial cell ingrowth into the matrigel. The neovasculature appears functional as
vessels are lectin-FITC-positive. With the addition of VEGF/FGF, the functional neovasculature showed signs of more vigorous growth and
mature architecture, and the engraftment of 4E into the vascular wall was dramatically enhanced. Many of the engrafting 4E cells were
green fluorescence-positive, reflecting their endothelial differentiation indicated by either one or both of the events, the expression of Tie2-
GFP or/and Lycopersicon Esculentum lectin-FITC (LEL-FITC) staining. The high-magnification images are inserted on the right panel and show
the framed area. Growth factor (GF)-depleted matrigel alone did not support any visible invasion of endothelial cells or ingrowth of
capillaries. The 4E cells were pre-labeled with cell tracker CM-DiI (red fluorescence).
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GFP or LEL-FITC (readily distinguishable due to the
cytosolic vs luminal membrane fluorescence, respectively).
However, even a potential overlap in signals would not
hinder the interpretation of the results as either staining
originated from endothelial cells. Furthermore, ultrathin
deconvoluted fluorescent microscopy analysis confirmed that
some of the cells incorporated into the neovasculature in
the growth factor-containing matrigel were CM-DiI and
LEL-FITC double-positive (Figure 3). Thus, in the absence
of VEGF-A/FGF-2, 4E cells support angiogenesis by promot-
ing the host endothelial cell infiltration of angioreactors,
whereas in the presence of these growth factors, 4E cells
transdifferentiate into endothelial cells and participate in
vasculogenesis.
Transplantation of 4E cells in acute renal ischemia: transdif-
ferentiation to endothelial or aSMA-expressing cells
Next, we addressed the possibility of 4E cell participation in
vasculogenesis associated with tissue injury. Toward this end,
we studied the pro-angiogenic and renoprotective potential
of 4E cells using acute renal ischemia–reperfusion (I/R)
model. We first examined the engraftment of the CM-DiI-
labeled 4E cells in the ischemic kidney 3–30 days after
transplantation (Figure 4). The number of the engrafted CM-
DiI-labeled 4E cells was significantly higher in the ischemic
kidney compared with the contralateral non-ischemic kidney
3 days after transplantation (1.9±0.1 vs 0.2±0.1 cells per
mm2, respectively, Po0.01). This difference in 4E cell
engraftment to ischemic and contralateral non-clamped
kidney was maintained up to 30 days (Figure 4b). Tie2-
GFP signal was not detectable in kidney sections at 3–15 days
after I/R injury. In contrast, by 30 days after I/R injury,
9.2±3.1% of engrafted 4E cells expressed Tie2-GFP along the
peritubular capillary area, suggesting a possible endothelial
transdifferentiation of MSC (Figure 4c). In addition, the
examination of the aSMA expression indicated that about
45±6–55±1% of the engrafted 4E cells became aSMA-
positive 15–30 days after I/R injury (Figure 5).
In the next series of experiments, we examined functional
consequences of 4E cell transplantation in mice with bilateral
I/R injury. Thirty minutes of bilateral ischemia induced
severe renal dysfunction as judged by a significant increase in
plasma creatinine levels (Figure 6a): from the baseline of
0.24±0.07 to 1.92±0.22 mg per 100 ml 1 day after clamping.
Compared with control ischemic mice, animals that received
4E cells after I/R injury had a significantly lower plasma
creatinine levels 2–3 days after ischemic injury (24–48 h after
cell transplantation), suggesting an early renoprotection
afforded by the transplanted cells. To obtain insights into
the mechanism of 4E-mediated renoprotection in I/R injury,
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Figure 3 | In vivo contribution of 4E cells to neovascularization. To better visualize the participation of 4E cells in the neovascularization,
angioreactors were also analyzed using deconvolution microscopy. Images on the left represent consecutive fluorescence microscopy of
the LEL-FITC and CM-DiI-labeled cells as well as the merged image. The image on the right (top panel) shows a three-dimensional
reconstruction of the angioreactor, representing stacks of frames spanning 40 mm in thickness. The double-positive cell in the cross of the
vertical and horizontal lines is indicated by the arrows in the cross-sectional X- and Y-view strips. The image in the lower right panel shows
an enlarged area framed in the merged image.
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we examined the rates of tubular epithelial cell (TEC)
proliferation and apoptosis in the kidneys of control and
4E-transplanted mice. As shown in Figures 4e and 6c,
transplantation significantly increased the number of pro-
liferating Ki-67-positive TEC (255±22 vs 135±16 cells per
mm2, respectively, Po0.05) and simultaneously reduced the
number of apoptotic TEC on TUNEL (terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labeling)
assay (58±7 vs 117±13 cells per mm2, respectively,
Po0.05). At 15 and 30 days post-ischemia, the level of
plasma creatinine was similar in both groups and indis-
tinguishable from the baseline (data not shown).
To further assess the role of 4E cells in renoprotection,
microvascular density and the degree of fibrosis were
examined in ischemic and control kidney sections processed
for the expression of CD31 and stained with Masson’s
trichrome stain. As summarized in Figure 7, the degree
of microvascular rarefaction was significantly reduced in
4E-transplanted vs control kidneys at early (3 days) time
points after ischemia, but later these differences disappeared.
Trichrome staining revealed comparable levels of fibrosis
between transplanted and control post-ischemic kidneys at
day 30 (1.3±0.3 vs 1.6±0.3 in cortex and 1.4±0.3 vs
1.9±0.4 in medulla, respectively). Plasma and renal tissue
levels of pro- and anti-inflammatory cytokines, such as
TNF-a, IL-1a, IL-b, IL-6, KC, and IL-10, did not show
significant difference between control and 4E-transplanted
mice (data not shown). However, compared with control, 4E-
transplanted mice showed a fivefold increase in renal tissue
VEGF expression at 3 days after I/R injury (Figure 7d). In
contrast, the plasma VEGF level did not show any significant
difference between the two groups (9.5±1.3 vs 9.4±2.4 pg/
ml). These data indicated that the fact that 4E cells-afforded
renoprotection is, in part, due to the local VEGF paracrine
effect, resulting in the preservation of peritubular capillaries,
reduced apoptosis, and increased proliferation of TEC.
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Figure 4 | Analysis of the engraftment and transdifferentiation of transplanted 4E cells after I/R injury. The number of engrafted
CM-DiI-labeled 4E cells in peritubular capillaries of the unilateral ischemic kidney was compared with the contralateral non-ischemic control
3, 15, and 30 days after I/R injury. (a) Representative images of red fluorescent CM-DiI-labeled 4E cells (arrow) and Tie2-GFP fluorescence
of kidneys at different times after ischemia. (b) The summary of quantitative analysis of engrafted cells and the appearance of GFP
fluorescence. (c) After 30 days, 9.2±3.1% of the engrafted CM-DiI-labeled cells become Tie2-GFP-positive. Arrows indicate CM-DiI- and/or
GFP-expressing cells. Nuclei were stained with DAPI. Original magnification was  600. *Po0.05 vs control. n¼ 6 mice for each group,
values are mean±s.e.m.
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DISCUSSION
The focus of this study was on the potential of a kidney-
derived MSC line, 4E cells previously obtained and
characterized by us,8 to differentiate toward endothelial
lineage, both in vitro and in vivo, and their contribution to
organ repair after ischemic injury. Previous studies have
shown that MSCs isolated mainly from the bone marrow, as
well as various adult tissues, are clonogenic, plastic-adherent,
multipotent cells capable of differentiating in vitro to a
variety of cell lineages, including adipocytes, osteoblasts,
chondrocytes, myoblasts, neural tissue, and endothelial
cells.4,13–18 These unique properties have implicated MSC as
promising candidates for cell-based therapy in the treatment
of a range of chronic, degenerative, and ischemic diseases.19
Benefits of MSC transplantation were demonstrated in
clinical trials 20 and various animal experiments,21,22 but
the underlying mechanisms remain elusive. With regard to
the ischemic disease, it has been shown that transplantation
of stem or progenitor cells can improve neovascularization
and recovery of ischemic tissue and organ.23,24 The following
four hypotheses currently ascribe this regenerative mechan-
isms to: (a) engraftment and differentiation of the adminis-
tered cells into the cellular components of the host tissue or
organ;23,25 (b) therapeutic fusion with the existing host
cells;4,26–28 (c) release of paracrine signals from the adminis-
tered cells;29 and (d) stimulation of endogenous repair
through the regeneration of stem cell niches in the local
tissue.30 The in vitro findings presented herein appeared to
highlight an additional mechanism, that is, vasculogenic
potential of MSC.
Focusing on the angiogenesis and ischemic disease, the
data presented provide three independent lines of evidence
demonstrating the angiogenic and vasculogenic potential of
4E cells: (1) in vitro transdifferentiation to endothelial-like
and smooth muscle-like cells; (2) in vivo neovascularization
of angioreactors; and (3) in vivo engraftment and transdiffer-
entiation toward endothelial lineage after acute ischemic
renal injury. Our data clearly demonstrate the propensity of
MSC toward endothelial differentiation, as well as paracrine
angiogenic chemoattraction.
It has been suggested previously that MSC may be one of
the sources for circulating endothelial progenitor cells.4,31
Under certain conditions, they can also directly differentiate
to endothelial cells.11 Our previous data showed that 4E clone
of MSC isolated from the kidney secrete angiogenic factors in
culture and support endothelial cell growth and angiogen-
esis.8 Our in vivo angioreactor experiments with 4E cells are
consistent with this notion, and hence support the paracrine
mechanism of angiogenesis stimulated by MSC. Further-
more, our experiments also demonstrate an in vivo
differentiation of 4E cells to the endothelial cells. In a sharp
contrast to the rarely detected 4E cells when cultured in the
growth factor-depleted matrigel, once VEGF-A/FGF-2 is
present, 4E cells show signs of robust recruitment to and
endothelial differentiation in the neovasculature. It is well-
known that stem cell engraftment and endothelial differ-
entiation are growth factor-dependent processes highly
dependent on microenvironmental cues.32 This is further
emphasized by the fact that in the absence of added growth
factors to angioreactors, multiple capillaries are formed in
spite of only sporadic incorporation of 4E cells into the
functional neovessels (angiogenesis originating from the host
vessels), whereas in the presence of growth factors 4E cells
formed new vessels (vasculogenesis originating from
implanted 4E cells).
In a previous study involving tumor angiogenesis,
subcutaneous co-injection of bone marrow MSC with U-87
glioma cells in nude mice resulted in the formation of highly
vascularized tumors.33 In addition to the regulation through
paracrine mechanism, it was documented that bone marrow
MSC can be differentiated into CD31-positive cells, which
constitute about 5% of the neovasculature of the solid tumor.
Our experiments show that a significant proportion of 4E
cells in the vicinity of the neovasculature were recruited into
the vascular wall and differentiated into endothelial cells once
VEGF/FGF was provided.
One of the characteristics of MSC is their ability to home
to the sites of tissue damage or inflammation.34 Using acute
renal ischemia model, we observed significantly higher
engraftment of the transplanted 4E cells in the ischemic
kidney compared with the non-ischemic contralateral control
at all tested time points over 1 month experimental period.
These data support the concept that stem cell engraftment is
highly dependent on local microenvironmental cues. Indeed,
the 4E cells express CXCR48 and upregulated renal SDF-1
signals after ischemic injury may have contributed to their
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Figure 5 | Immunofluorescence analysis of the expression
of aSMA in engrafted 4E cells in ischemic kidney.
(a–c) Representative images of CM-DiI- and/or aSMA-expressing
4E cell engrafting ischemic kidneys (merged image shown in
panel c with the nuclear DAPI staining) 30 days after I/R injury.
(d) Quantitative analysis of results at 3–30 days after I/R injury.
Original magnification was  400. *Po0.01 vs 3 days. n¼ 4
in each group, values are mean±s.e.m.
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preferential homing and engraftment. This ability of MSC to
home to the sites of acute tissue injury has also been
demonstrated in the settings of bone fracture,34,35 cerebral
ischemia,36 as well as the infarcted myocardium.37
Because (a) there are no consistently reliable markers
of these cells in situ and (b) a few available markers of these
cells may disappear after cell differentiation, the strategy we
elected was to isolate and expand clonal 4E MSC ex vivo and
transfuse them in vivo as a surrogate for a behavior of the
resident cells. Compared with the acquisition of endothelial
lineage markers in both the in vitro cell culture and the
in vivo angioreactor experiments, the endothelial transdiffer-
entiation rate in our ischemic renal injury experiments is less
robust: only 9% of the engrafted CM-DiI-labeled 4E cells in
the ischemic kidney become Tie2-GFP-positive 30 days after
transplantation, indicating their endothelial transdifferentia-
tion. In comparison, the percentage of the engrafted 4E cells
that become aSMA-positive 15–30 days after transplantation
is higher. I/R injury can induce a wide range of gene
expression including VEGF in the kidney.38 These factors
may orchestrate the observed 4E-to-endothelial or 4E-to-
smooth muscle cell lineage transdifferentiation in the
ischemic kidney. One could speculate that the composition
of the post-ischemic microenvironment may be less favorable
for 4E-to-endothelial transdifferentiation than the conditions
found in our cell culture and angioreactor experiments.
Nonetheless, the functional assessment of the ischemic
kidney points out to the amelioration of renal dysfunction
2–3 days after ischemic episode by the 4E cell transplantation
as judged by the plasma creatinine level. It is clear that the
observed accelerated functional improvement is unrelated to
4E cell transdifferentiation to the endothelial cells because the
renoprotective effect occurs 24–48 h after 4E cell transplanta-
tion, as opposed to the much delayed transdifferentiation.
One possible explanation for the early benefits of 4E cell
delivery in the context of recovery from acute renal injury is
the previously described paracrine mechanism.12,18,39 Indeed,
4E cell transplantation was associated with increased
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Figure 6 | Accelerated renal functional recovery by 4E cell transplantation after I/R injury. (a) The measurement of plasma creatinine
concentration demonstrated a significantly lower creatinine level in transplanted mice 2–3 days after I/R renal injury. The shaded line
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proliferation and reduced apoptosis of TECs. Moreover,
microvascular rarefaction in the post-ischemic kidney was
significantly reduced in the 4E-transplanted ischemic group,
in synchrony with a fivefold increase in the renal expression
of VEGF, in the absence of changes in systemic VEGF level.
All this argues in favor of a local paracrine effect of 4E cell
transplantation. In this regard, our data are in agreement
with results obtained by Togel et al.18 On the other hand, the
transdifferentiation potential toward the smooth muscle/
myofibroblastic lineage may represent the mechanistic
explanation for the long-term pro-fibrotic sequelae reported
in renal ischemia.40 It is quite possible that the proportion of
MSC transdifferentiating toward the endothelial vs myofi-
broblastic lineage is an important determinant of the
outcome of renal ischemia.
In summary, kidney-derived MSCs (4E cells) are vasculo-
genic as demonstrated by the analysis of implanted matrigel
angioreactors supplemented with VEGF-A/FGF-2 growth
factors. Despite this, in the context of acute ischemic injury,
the transplantation of kidney-derived MSC (4E cell) affords
renoprotection not through vasculogenesis, but rather
through local paracrine effects that promote renal regenera-
tion and prevent microvascular dropout.
MATERIALS AND METHODS
Animal studies
The animal study protocol was in accordance with the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Animal Care and Use
Committee. Adult (8–20 weeks old) Tie-2/GFP mice41 (FVB/NJ
strain) were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). As the expression of GFP protein is under the control of
Tie2 gene promoter/enhancer elements, it is hence present in
virtually all endothelial cells where the Tie2 gene is constitutively
expressed. This mouse model provided a convenient tool for
monitoring the endothelial differentiation process. Animals were
kept under temperature-controlled conditions of 12-h light/dark
cycle, with water and food ad libitum. A separate group of mice was
used as hosts of angiogenic cylinders (angioreactors) implanted
subcutaneously as detailed below. Prior to the killing, mice were
anesthetized with a combination of ketamine and xylazine and
received intraperitoneal injection of 250 U/kg of heparin. Blood was
collected from the left ventricle, and animals were flushed with 40 ml
phosphate-buffered saline (PBS).
Isolation and culture of MSC–4E cells
Using a technique for culturing multipotent mesenchymal cells from
adult tissues,1,42 we have previously isolated and cloned fibroblast-
like cell line (referred to as 4E) from the kidney of adult Tie-2/GFP
mouse. These 4E cells could be differentiated along multiple
mesodermal lineages, including adipocytes, osteoblasts, as well as
endothelial cells. Analysis of the expression of surface antigens, growth
factor receptors, cytoskeletal proteins, and transcription factors
revealed a pattern that was compatible with both mouse MSCs and
renal stromal progenitor cells.8 4E cells were maintained on gelatin-
coated dishes in minimum essential medium (MEM) with 10% horse
serum (Gem Biotech, Woodland, CA, USA) and consistently
expressed the above markers between passages 10 and 25.
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Figure 7 | Microvascular rarefaction in post-ischemic kidneys. Representative images of CD31 staining in control (a) and 4E-injected
(b) mice on day 3 after I/R injury. (c) To quantify vascular dropout in post-ischemic kidneys, microvascular rarefaction index was calculated
as detailed in Materials and Methods. Three days post-ischemia microvasculature was significantly preserved by the administration of
4E cells compared with un-treated kidneys. At later times, 15 and 30 days post-ischemia, the differences in rarefaction index disappeared.
(d) 4E-Transplanted mouse kidneys showed a fivefold increase in renal VEGF expression at 3 days after I/R injury. In contrast, plasma
VEGF level did not show any significant difference between the two groups. Original magnification was  400. *Po0.05 vs control.
n¼ 4 in each group, values are mean±s.e.m.
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Flow cytometry analysis
Expression of GFP and staining of CD31 with phycoerythrin-
conjugated antibody (BD Biosciences, Rockville, MD, USA) on the
4E cells following 1 month of three-dimensional matrigel culture
were measured using fluorescence-activated cell sorting as pre-
viously described.8 Each analysis included at least 10,000 events and
was performed on at least two separate cell preparations.
In vitro angiogenesis assay
Cultured 4E cells were detached with trypsin/EDTA, viable cells
counted, and single-cell suspension (at a density of 2 105 cells per
ml) was prepared using EGM-2 medium (Clonetics, San Diego, CA,
USA) or MSC culture medium. A volume of 200ml per well of
growth factor-depleted, phenol red-free Matrigel (BD Biosciences,
San Jose, CA, USA) was plated in four-well chamber slides (BD
Biosciences) and incubated at 37 1C for 15 min. The same volume
(200 ml) of cell suspension was plated on Matrigel. For comparison,
the same amount of cells was also plated on chamber slides that were
pre-coated overnight with fibronectin (BD Biosciences) at 4 1C.
Endothelial capillary formation and the GFP signal were monitored
using an inverted fluorescence microscope every 3 days over 1
month period. By the end of observations, the cells were washed
with PBS and stained with phycoerythrin-labeled anti-mouse CD31
(PECAM-1, BD Biosciences) or a-SMA antibody (Dako North
American, Carpinteria, CA, USA) with appropriate phycoerythrin-
conjugated secondary antibody applied. After repeated washes with
PBS, the chamber slides were examined and images obtained using
Nikon fluorescent microscope (Eclipse TE2000-U) equipped with a
digital camera (Spot model 4.2; Diagnostic Instruments, Sterling
Heights, MI, USA).
In vivo angiogenesis and vasculogenesis studies using
angioreactors
The directed in vivo angiogenesis assay was adapted for our in vivo
angiogenesis study. Matrigel filling and cylinder implantation
procedure were conducted under sterile conditions following the
previously published protocol43 and the manufacturer’s instructions
(Trevigen Inc., Gaithersburg, MD, USA). In brief, the sterile
implant-grade silicone cylinders, referred to as angioreactors, were
filled at 4 1C with 20 ml of matrigel containing FGF-2 (3.75 ng),
VEGF-A (1.25 ng), and heparin (200 ng) with or without admixed
4E. The 4E cells were labeled with red fluorescent cell tracker CM-
DiI (Molecular Probes, Eugene, OR, USA) and mixed with the
matrigel at a density of 3000 cells per angioreactor. Cylinders were
then incubated at 37 1C for 1 h to allow gel formation, and
implanted subcutaneously into the dorsal flank of FVB mice. For
each implantation experiment, four types of angioreactors were
prepared: matrigel or growth factor alone, 4E/matrigel alone, and
4E/matrigel with VEGF-A/FGF-2. Fifteen days after implantation,
angioreactors were harvested from the host mice. To visualize the
ingrowth of the neovasculature from the host mice, 5 min before
killing 100ml of LEL-FITC (1 mg/ml in 10 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), 150 mM NaCl, pH
7.5; Sigma, St Louis, MO, USA) was injected via tail vein to label the
patent systemic vascular endothelium of the host mice. The collected
angioreactors were fixed in 4% paraformaldehyde in PBS overnight
at room temperature. The sealed bottom portion of the angioreactor
was trimmed away with scissors. The fixed matrigel plugs were
carefully removed. After washing with PBS, the gel plugs were whole
mounted on chamber slides in glycerol/PBS and gently flattened
under the coverslip. The slides were examined and images captured
under a fluorescence microscope (Nikon) or confocal microscope
(Zeiss Aniovert 200 inverted fluorescence microscope equipped with
Zeiss Axiocam digital camera, Carl Zeiss, Hamburg, Mecklerburg,
Germany) for deconvolution analysis. Z-stack images at 0.5 mm per
step were collected using  10 fluorescence objective lens and
analyzed with Axiovision 4.4 software.
Transplantation of 4E cells in a model of renal ischemia
Unilateral or bilateral renal ischemia in male FVB/NJ mice (aged
8–20 weeks) was performed according to previously detailed
protocol.8 Briefly, mice were anesthetized, a midline laparotomy
and bilateral or unilateral renal pedicle clamping was performed
with microserrefines (Fine Science Tools, Foster City, CA, USA). The
abdomen was covered with gauze moistened in PBS, and throughout
the ischemia period, animals were kept well hydrated with saline and
at a constant temperature (B37 1C) using a heated thermoplate
(Tokai Hit, Fujinomiya-shi, Shizuoka-ken, Japan). After 30 min of
ischemia, the clamps were removed, and reperfusion was confirmed
visually. CM-DiI-labeled 4E cells (106 cells per animal) were injected
intravenously via tail vein 24 h after reperfusion. Mice were killed at
different time points between 1 and 30 days after renal I/R injury,
blood samples were obtained and kidneys removed for further
analyses. Plasma creatinine concentration was determined using a
colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA)
according to the manufacturer’s protocol.
Immunofluorescent and immunohistochemical analysis
Kidneys were fixed in 4% paraformaldehyde overnight at 4 1C,
transferred to PBS containing 30% sucrose (overnight at 4 1C),
embedded in OCT (Tissue Tek; Sakura Finetek, Torrance, CA, USA)
and stored at 80 1C until analysis. Cryosections (10–20 mm) were
used for immunofluorescent and immunohistochemical analysis.
The identification of engrafted transplanted 4E cells was done by
detecting red fluorescent CM-DiI-labeled cells and the presence of
GFP signal by fluorescence microscopy of kidney sections. To detect
the expression of aSMA, sections were stained with mouse
monoclonal anti-aSMA (1:250, Dako, Carpinteria, CA, USA), and
tubular cell proliferation in the post-ischemic kidney was identified
by staining sections with rabbit anti-Ki-67 polyclonal antibody
(Abcam, Cambridge, MA, USA; 1:50). TUNEL assay using an In Situ
Cell Death Detection Kit, TMR red (Roche, Indianapolis, IN, USA)
was used to detect tubular cell apoptosis in post-ischemic kidney.
Sections were screened for positive nuclei under a fluorescence
microscope, and 20 random fields in the corticomedullary area were
counted for every kidney at  40 magnification. Staining for
peritubular capillary endothelial cells was performed on 20 mm
cryosections. Briefly, endogenous peroxidase activity and nonspe-
cific binding were blocked, and sections were incubated overnight at
4 1C with rat anti-mouse CD31 antibody (MEC 13.3, BD
Biosciences, 1:50), followed by incubation at room temperature
with peroxidase-conjugated donkey anti-rat antibody (1:200,
Jackson ImmunoResearch, West Grove, PA, USA) and chromogenic
substrate 3,30-diaminobenzidine (Dako). The sections were counter-
stained with hematoxylin and mounted. Negative control received
similar treatment with omission of the primary antibodies.
Quantification of peritubular capillary loss was performed by
calculating the rarefaction index as described.44 The CD31-
immunostained sections were examined through 10 10 grid under
a  40 objective. Each square within the grid that did not contain
CD31-positive capillary was counted. At least 20 fields in the cortex
and outer medulla were examined on the cross-section of each
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kidney, and a mean score per section was calculated. This scoring
system, thus, inversely reflects peritubular capillary rarefaction,
whereby low values represent intact capillaries and higher values
indicate loss of capillaries (minimum possible capillary score is 0,
and the maximum score is 100). The interstitial fibrosis was assessed
with Masson’s trichrome staining at low-power view ( 150) and
scored by an investigator blinded to the experimental design using a
semi-quantitative scale (0, absent; 1, o25% of specimen area; 2,
25–50% of specimen area; 3, 450% of specimen area).
Renal tissue and plasma cytokine measurements
Snap-frozen decapsulated kidneys were lysed with RIPA buffer
(1 PBS, 1% Nonidet P-40, 0.5% sodium deoxylate, 0.1% SDS, and
protease inhibitor), homogenized, and incubated at 4 1C for 30 min.
Homogenates were subsequently centrifuged at 1500 g at 4 1C
for 15 min, and supernatants and plasma were stored at 80 1C
until assays were performed. Multiplexed cytokine measurements
for renal tissue homogenates and plasma were performed using
multiplex assay kit (MCYTO-70K-13, Millipore, St Charles, MO,
USA), which allowed the simultaneous quantification of the
following analytes: TNF-a (Tumor Necrosis Factor a), Interleukin
(IL)-1a, IL-b, IL-6, KC, and IL-10. VEGF was measured using
mouse single-plex VEGF Beadmates (46-196; Millipore). All analytes
were tested individually and in combination to ensure that there
were no cross-reactions. All measurements were performed in
duplicate. The plates were analyzed using Luminex IS100 analyzer
(Luminex Inc., Austin, TX, USA). The data were saved and evaluated
as median fluorescence intensity (MFI) using appropriate curve-
fitting software (Luminex 100IS software version 2.3). A five-
parameter logistic method with weighting was used. Cytokine and
VEGF levels were corrected for the amount of protein present using
the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA,
USA) with IgG as standard.
Statistical analysis
Data are expressed as mean±s.e.m. Differences between the groups
were analyzed by analysis of variance or the Kruskal–Wallis test using
SPSS 11.0 (SPSS, Chicago, IL, USA). A P-value less than 0.05 was
considered statistically significant.
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